Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Lisen Therapeutics Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is being handled by 1 distinct examiner, YOO, SUN JAE. The prosecution is localized within 1 distinct art unit, reflecting a very specific technical focus for this particular filing. Because there is only 1 pending office action, the company's current interaction with the patent office is highly concentrated on this single case.
YOO, SUN JAE is the busiest examiner for the portfolio, as they are responsible for the 1 pending office action currently on record. This examiner's individual review will determine the outcome for the company's current efforts in the Biotechnology & Pharmaceuticals field. The alignment of the examiner and the art unit for the 1 pending action suggests a focused prosecution path. Practitioners can dedicate their resources to understanding the specific tendencies of YOO, SUN JAE within that single art unit. This lack of diversity in examiners and art units simplifies the administrative burden but places high importance on the single pending action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18770694 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | YOO, SUN JAE | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18770694 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | YOO, SUN JAE | 1621 | §102§112 | Non-Final OA | — | Pending | Jul 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLisen Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sun Jae Yoo has the most, with 1 of Lisen Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
